Sagimet Biosciences Stock
Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases.
Sign up today and learn more about Sagimet Biosciences Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Sagimet Biosciences Stock
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a pipeline of proprietary FASN inhibitors.
Funding History
| May 2007 | $7.6M |
|---|---|
| July 2009 | $30.0M |
| January 2012 | $20.0M |
| October 2012 | $8.1M |
| June 2013 | $20.0M |
| December 2014 | $28.5M |
| July 2016 | $5.4M |
| February 2019 | $18.0M |
| August 2019 | $7.0M |
| December 2020 | $69.0M |
| February 2021 | $80.0M |
Management
Member of the Board of Directors
Beth Seidenberg
CEO
George Kemble
Board Member
Matthew McAviney
Board Member
Ari Helenius
Chairman
David Mott
Co-Founder
Urs Greber
Member of the Board of Directors
Richard Klausner
Co-Founder
Lucas Pelkmans
Board Member
James F. Young
Board Member
Robert Garland
Chief Scientific Officer
George Kemble
CFO and Head Corporate Development
Dennis Hom
Investor
Sara Nayeem
Board Member
Gordon Ringold
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
